TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27271870

Group type: EXPERIMENTAL
Intervention: Distributed mental practice (20 min of MP occurring three times/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Massed mental practice (60 min of MP during a single daily session)
Number of subjects: 27
Study: 24385079

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (dose A: 3 injections of 2 U in 0.05 mL of normal saline per injection)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (dose B: 3 injections of 4 U in 0.05 mL of normal saline per injection)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (both doses)
Number of subjects: 58
Study: 23607773

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TrA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 20521988

Group type: EXPERIMENTAL
Intervention: vanilla soy milk (n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: reduced-fat dairy milk (n = 16)
Number of subjects: 32
Study: 17499863

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 110
Study: 16182833

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cyclosporine microemulsion (CsA‐ME)
Number of subjects: 205
Study: 12861072

Group type: EXPERIMENTAL
Intervention: Exposure to native Mandarin Chinese speakers in 12 laboratory sessions
Number of subjects: 9

Group type: COMPARATOR
Intervention: Exposure to recorded Mandarin (audiovisual or audio-only)
Number of subjects: 9
Study: 10386821

Group type: EXPERIMENTAL
Intervention: T enanthate (100 mg IM, weekly) + LNG 125 microg by mouth, daily
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: T enanthate (100 mg IM, weekly) + LNG 250 microg by mouth, daily
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: T enanthate (100 mg IM, weekly) + LNG 500 microg by mouth, daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: T enanthate (100 mg IM, weekly) + Placebo LNG
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All groups (LNG 0, 125, 250, 500)
Number of subjects: 72
Study: 8767366

Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet
Number of subjects: 302

Group type: COMPARATOR
Intervention: Conventional omnivorous diet
Number of subjects: 302
Study: 1505563

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg b.i.d. and 20 mg b.i.d. combined
Number of subjects: 20
Study: 6360754

Group type: EXPERIMENTAL
Intervention: HBIG (0.5 ml at birth, three months, and six months)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: HBIG (1.0 ml at birth only)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 31925605

Group type: EXPERIMENTAL
Intervention: Heart Matters intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Delayed intervention control group
Number of subjects: 143
Study: 31101097

Group type: EXPERIMENTAL
Intervention: Bouldering psychotherapy (BPT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Home-based exercise program (EP)
Number of subjects: 240
Study: 27887806

Group type: EXPERIMENTAL
Intervention: Coping and communication‐enhancing intervention (CCI)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 352
Study: 26313450

Group type: EXPERIMENTAL
Intervention: ranirestat 40 mg/day
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: ranirestat 80 mg/day
Number of subjects: 800

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: ranirestat (combined groups)
Number of subjects: 800
Study: 23962673

Group type: EXPERIMENTAL
Intervention: Process narratives
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Experience narratives
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control condition (no stories)
Number of subjects: 300
Study: 21420107

Group type: EXPERIMENTAL
Intervention: Active laser acupuncture
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo treatment with red light and skin contact
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo treatment with red light without skin contact
Number of subjects: 31
Study: 19125214

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the cerebellum
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study: 16421366

Group type: EXPERIMENTAL
Intervention: Tenofovir DF, emtricitabine, and efavirenz
Number of subjects: 517

Group type: COMPARATOR
Intervention: Zidovudine, lamivudine, and efavirenz
Number of subjects: 517
Study: 14765577

Group type: EXPERIMENTAL
Intervention: English version of the Kuwait University Anxiety Scale
Number of subjects: 74

Group type: COMPARATOR
Intervention: Arabic version of the Kuwait University Anxiety Scale
Number of subjects: 74
Study: 10642965

Group type: EXPERIMENTAL
Intervention: Daily membrane sweeping (group II)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Daily dinoprostone (Cervidil) vaginal inserts (group I)
Number of subjects: 182
Study: 9032861

Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery with marginal dose of 25-30 Gy
Number of subjects: 130
Study: 1505293

Group type: EXPERIMENTAL
Intervention: Famotidine (1 mg/kg/day)
Number of subjects: 10
Study: 6429876

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (20 mg) and ethinylestradiol (0.04 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NET-AC) and ethinylestradiol (EE2) in an open trial
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NET-AC) and ethinylestradiol (EE2)
Number of subjects: 25
Study: 30809971

Group type: EXPERIMENTAL
Intervention: Hot water extract of Curcuma longa (WEC)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: WEC + curcumin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: WEC
Number of subjects: 47

Group type: COMPARATOR
Intervention: WEC, WEC + curcumin, Placebo
Number of subjects: 47
Study: 30035582

Group type: EXPERIMENTAL
Intervention: #Tamojunto intervention (12 weekly classes)
Number of subjects: 6391

Group type: COMPARATOR
Intervention: Control (no prevention program)
Number of subjects: 6391
Study: 29231296

Group type: EXPERIMENTAL
Intervention: 40-min penetration moxibustion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 60-min penetration moxibustion
Number of subjects: 60
Study: 27128613

Group type: EXPERIMENTAL
Intervention: MF/F‐MDI (mometasone furoate 800 µg and formoterol fumarate 20 µg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: MF‐DPI (mometasone furoate 800 µg)
Number of subjects: 12
Study: 22349525

Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa (DTPa‐HBV‐IPV/Hib)
Number of subjects: 702
Study: 19617580

Group type: EXPERIMENTAL
Intervention: Psychoeducational interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonspecific factors (e.g., patient expectations, therapeutic alliances)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing interventions
Number of subjects: 0
Study: 18288274

Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 34
Study: 16271551

Group type: EXPERIMENTAL
Intervention: Individually fitted shoe inserts
Number of subjects: 33

Group type: COMPARATOR
Intervention: No correction of LLD (Control)
Number of subjects: 33
Study: 11864860

Group type: EXPERIMENTAL
Intervention: Test meals fortified with ferrous fumarate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test meals fortified with ferrous sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test meals fortified with NaFeEDTA
Number of subjects: 0
Study: 10357501

Group type: EXPERIMENTAL
Intervention: Coronary artery revascularization (either bypass surgery or angioplasty)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 620
Study: 8584996

Group type: EXPERIMENTAL
Intervention: FXIII from plasma
Number of subjects: 13

Group type: COMPARATOR
Intervention: FXIII from placenta
Number of subjects: 13
Study: 2338028

Group type: EXPERIMENTAL
Intervention: Non-lacquered tablet (M 250 mg, P 25 mg, S 500 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lacquered tablets (M 125 mg, P 12.5 mg, S 250 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison with previously published data
Number of subjects: 6
Study: 389420

Group type: EXPERIMENTAL
Intervention: Training plus verapamil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Training plus placebo
Number of subjects: 40
Study: 31349850

Group type: EXPERIMENTAL
Intervention: ProLife programme (Motivational Interviewing counselling sessions followed by SMS messages)
Number of subjects: 696
Study: 28444456

Group type: EXPERIMENTAL
Intervention: Leucine supplementation (3.0 g/day post-training)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 20
Study: 26184302

Group type: EXPERIMENTAL
Intervention: Cereal breakfast (118 or 236 kcal)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No breakfast
Number of subjects: 24
Study: 23615317

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 7002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7002
Study: 21719599

Group type: EXPERIMENTAL
Intervention: MRD standard risk (MRD-SR) - negative at day 33 and day 78
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: MRD intermediate risk (MRD-IR) - positive at day 33 or 78 and < 10(-3) at day 78
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: MRD high risk (MRD-HR) - ≥ 10(-3) at day 78
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: MRD negative at TP2
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: MRD ≥ 10(-3) at TP2
Number of subjects: 464
Study: 19700947

Group type: EXPERIMENTAL
Intervention: Prazosin (mean dose: 5.7 ± 0.9 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (mean dose: 5.6 ± 1.2 mg/day)
Number of subjects: 22
Study: 16918615

Group type: EXPERIMENTAL
Intervention: 0.025 microg/cm2 (2 p.p.m.) of MCI/MI/unit area of the skin for 4 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.094 microg/cm2 (7.5 p.p.m.) of MCI/MI/unit area of the skin for 4 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 35
Study: 12163794

Group type: EXPERIMENTAL
Intervention: Propofol sedation (1-4 mg x kg(‐1) x hr(‐1))
Number of subjects: 20
Study: 10023893

Group type: EXPERIMENTAL
Intervention: Structured interdisciplinary assessment with referral to relevant services (n=184)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Usual care only (n=213)
Number of subjects: 397
Study: 7772482

Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inert gel base
Number of subjects: 0
Study: 2185611

Group type: EXPERIMENTAL
Intervention: Computerized administration of SMAST‐13
Number of subjects: 280

Group type: COMPARATOR
Intervention: Paper-and-pencil administration of SMAST‐13
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Computerized administration of CAGE
Number of subjects: 280

Group type: COMPARATOR
Intervention: Paper-and-pencil administration of CAGE
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Computerized administration of quantity-frequency scale
Number of subjects: 280

Group type: COMPARATOR
Intervention: Paper-and-pencil administration of quantity-frequency scale
Number of subjects: 280
Study: 378509

Group type: EXPERIMENTAL
Intervention: Ticrynafen (TCN) 125 mg daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Probenecid (PBC) 500 or 1,000 mg daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ticrynafen (TCN)
Number of subjects: 9
Study: 30010923

Group type: EXPERIMENTAL
Intervention: FBT incorporating AAT strategies (FBT-AAT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: FBT
Number of subjects: 84
Study: 27692638

Group type: EXPERIMENTAL
Intervention: Lorcaserin extended-release 20-mg once-daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lorcaserin extended-release under fed conditions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lorcaserin extended-release under fasted conditions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lorcaserin immediate-release 10-mg BID
Number of subjects: 36
Study: 25642918

Group type: EXPERIMENTAL
Intervention: SSRIs treatment
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Combination of neuroendocrine factors, clinical characteristics, and gene polymorphisms
Number of subjects: 290
Study: 23998714

Group type: EXPERIMENTAL
Intervention: CRT (Cardiac-resynchronization therapy)
Number of subjects: 809

Group type: COMPARATOR
Intervention: Control (CRT capability turned off)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: CRT
Number of subjects: 809

Group type: COMPARATOR
Intervention: Control
Number of subjects: 809
Study: 20381665

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study: 18218291

Group type: EXPERIMENTAL
Intervention: Deferasirox without dispersion
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Deferasirox dispersed in orange juice
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Deferasirox dispersed in apple juice
Number of subjects: 28

Group type: COMPARATOR
Intervention: Deferasirox dispersed in water (reference)
Number of subjects: 28
Study: 16650240

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 96
Study: 12867108

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1701

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1701

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 1701
Study: 10214099

Group type: EXPERIMENTAL
Intervention: Full capitation reimbursement incentive
Number of subjects: 710

Group type: COMPARATOR
Intervention: Fee-for-service reimbursement incentive
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Utilization review scenarios
Number of subjects: 710

Group type: COMPARATOR
Intervention: Insurance form completion scenarios
Number of subjects: 710
Study: 7541916

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐6 (IL‐6) at doses of 0, 1, 2.5, or 5 micrograms/kg/d subcutaneously on days 4 to 13
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Granulocyte colony‐stimulating factor (G‐CSF) at a dose of 5 micrograms/kg/d subcutaneously beginning on day 4 until a postnadir absolute neutrophil count of more than 10 x 10(9)/L
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ifosfamide 2,000 mg/m2 with mesna 1,600 mg/m2 intravenously on days 1, 2, and 3, carboplatin 350 mg/m2 intravenously on day 1 only, and etoposide 75 mg/m2 intravenously on days 1, 2, and 3
Number of subjects: 15
Study: 2365468

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 154

Group type: COMPARATOR
Intervention: Aztreonam plus cefazolin
Number of subjects: 154
Study: 27064

Group type: EXPERIMENTAL
Intervention: Short-term salt depletion and peroral furosemide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bolus injection of propranolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Long-term treatment with propranolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Decrease in PRA on propranolol (bolus/long-term)
Number of subjects: 19
Study: 31765632

Group type: EXPERIMENTAL
Intervention: Anodal tsDCS (20 min, 2 mA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 16
Study: 30223023

Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 single injection (6 mL)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 357
Study: 28341759

Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg daily) in Cohort R (R1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg every 12 hours) in Cohort NR (NR1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ritonavir (CYP3A4 inhibitor)
Number of subjects: 10
Study: 26667367

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid (EPA) at 1,800 mg/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 95
Study: 23745525

Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline (HS) plus 0.1% hyaluronic acid (HA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 7% hypertonic saline (HS)
Number of subjects: 40
Study: 22768976

Group type: EXPERIMENTAL
Intervention: HCV positive patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HCV negative patients
Number of subjects: 60
Study: 19647862

Group type: EXPERIMENTAL
Intervention: 300-IR SLIT tablets
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 17880902

Group type: EXPERIMENTAL
Intervention: Interpretive labels (positive/abnormal results)
Number of subjects: 1688

Group type: COMPARATOR
Intervention: No interpretive labels (numeric results alone)
Number of subjects: 1688
Study: 14712427

Group type: COMPARATOR
Intervention: Vitamin D3 (alfacalcidol, 0.5 microg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin K2 (menatetrenone, 45 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamins D3 plus K2
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (prednisolone alone)
Number of subjects: 60
Study: 12466776

Group type: EXPERIMENTAL
Intervention: SpinT goniometer
Number of subjects: 23

Group type: COMPARATOR
Intervention: CROM instrument
Number of subjects: 23
Study: 9805724

Group type: EXPERIMENTAL
Intervention: New rationalised programme of antenatal care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 0
Study: 7645443

Group type: EXPERIMENTAL
Intervention: Reactivating occupational therapy in addition to functional rehabilitation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Functional rehabilitation alone
Number of subjects: 44
Study: 31425350

Group type: EXPERIMENTAL
Intervention: VGG19 model
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Best ensemble model
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-RB group
Number of subjects: 62
Study: 29090986

Group type: EXPERIMENTAL
Intervention: Negative pressure therapy (NPT) following cesarean section
Number of subjects: 467

Group type: COMPARATOR
Intervention: Historical control group (no NPT)
Number of subjects: 467
Study: 27626390

Group type: EXPERIMENTAL
Intervention: The Incredible Years School Age Program (12 weekly 2-hour sessions)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: All participants pre- and post-intervention
Number of subjects: 22
Study: 25650109

Group type: EXPERIMENTAL
Intervention: Light It Up advertisement
Number of subjects: 397

Group type: COMPARATOR
Intervention: Neutral comparison advertisement
Number of subjects: 397
Study: 23643576

Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Number of subjects: 11
Study: 20495141

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnoea (IH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional recovery (control)
Number of subjects: 30
Study: 19374795

Group type: EXPERIMENTAL
Intervention: Argatroban 0.02 mg kg(‐1) h(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Argatroban 0.04 mg kg(‐1) h(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Argatroban 0.06 mg kg(‐1) h(‐1)
Number of subjects: 10
Study: 16688993

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM)
Number of subjects: 0
Study: 15136383

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg daily for 21 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11291825

Group type: EXPERIMENTAL
Intervention: Manual tracking task using a hand-held stylus over a digitizing tablet
Number of subjects: 67
Study: 9108186

Group type: EXPERIMENTAL
Intervention: Pediatric formulation of ciprofloxacin (125 mg per capsule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 250 mg tablets of ciprofloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salivary concentrations of ciprofloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salivary concentrations as a surrogate measure
Number of subjects: 0
Study: 8275921

Group type: EXPERIMENTAL
Intervention: Medifoxamine (daily dose of 194 mg at day 28)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Imipramine (daily dose of 161 mg at day 28)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both Medifoxamine and Imipramine
Number of subjects: 98
Study: 2873890

Group type: COMPARATOR
Intervention: ACVP (doxorubicin, cyclophosphamide, and prednisolone in combination with vincristine)
Number of subjects: 247

Group type: COMPARATOR
Intervention: ACTP (doxorubicin, cyclophosphamide, and prednisolone in combination with teniposide)
Number of subjects: 247

Group type: COMPARATOR
Intervention: ACTVP (doxorubicin, cyclophosphamide, and prednisolone in combination with both vincristine and teniposide)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: ACTVP
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: ACVP
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: ACTP
Number of subjects: 247
Study: 29368152

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) followed by sentinel lymph node biopsy (SNB)
Number of subjects: 13396
Study: 27287209

Group type: EXPERIMENTAL
Intervention: Stepped Care (SC)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 156
Study: 24554737

Group type: EXPERIMENTAL
Intervention: Additional sulcus-fixated multifocal IOL (group A)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional multifocal IOL (group B)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54